IL1B and bacterial infectious disease: A variety of drugs have displayed efficacy in preventing osteolytic responses to WPs in vivo, particularly anti-resorptive agents targeting osteoclasts, such as bisphosphonates and osteoprotegerin (OPG) [36,37], and agents targeting pro-inflammatory signaling such as IL-1β [43] or NFκB activation [48], although these were assessed in the absence of a bacterial infection.